Neuroblastoma pp 243-256 | Cite as

Differentiation and Retinoids

  • Carol J. Thiele
  • C. Patrick Reynolds
Part of the Pediatric Oncology book series (PEDIATRICO)


Retinoic Acid Neural Crest Neural Crest Cell Retinoic Acid Receptor Human Neuroblastoma Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abemayor E, Sidell N (1989) Human neuroblastoma cell lines as models for the in vitro study of neoplastic and neuronal cell differentiation. Environ Health Perspect 80:3–15PubMedGoogle Scholar
  2. Cheung B, Hocker JE, Smith SA, Norris MD, Haber M, Marshall GM (1998) Favorable prognostic significance of high-level retinoic acid receptor beta expression in neuroblastoma mediated by effects on cell cycle regulation. Oncogene 17:751–759CrossRefPubMedGoogle Scholar
  3. Chomienne C et al (1990) All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood 76:1710–1717PubMedGoogle Scholar
  4. Cohen PS, Cooper MJ, Helman LJ, Thiele CJ, Seeger RC, Israel MA (1990) Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors. Cancer Res 50:6055–6061PubMedGoogle Scholar
  5. Cooper MJ, Hutchins GM, Cohen PS, Helman LJ, Mennie RJ, Israel MA (1990) Human neuroblastoma tumor cell lines correspond to the arrested differentiation of chromaffin adrenal medullary neuroblasts. Cell Growth Differ 1:149–159PubMedGoogle Scholar
  6. Cooper MJ, Steinberg SM, Chatten J, Evans AE, Israel MA (1992) Plasticity of neuroblastoma tumor cells to differentiate along a fetal adrenal ganglionic lineage predicts for improved patient survival. J Clin Invest 90:2402–2408PubMedGoogle Scholar
  7. Corazzari M, Lovat PE, Oliverio S, Pearson AD, Piacentini M, Redfern CP (2003) Growth and DNA damage-inducible transcription factor 153 mediates apoptosis in response to fenretinide but not synergy between fenretinide and chemotherapeutic drugs in neuroblastoma. Mol Pharmacol 64:1370–1378CrossRefPubMedGoogle Scholar
  8. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP (2000) High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6:1900–1908PubMedGoogle Scholar
  9. Erdreich-Epstein A et al. (2002) Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem 277:49531–49537PubMedGoogle Scholar
  10. Evans AE et al. (1999) Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin Cancer Res 5:3594–3602PubMedGoogle Scholar
  11. Finklestein JZ et al. (1992) 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group. Med Pediatr Oncol 20:307–311PubMedGoogle Scholar
  12. Gaetano C, Matsumoto K, Thiele CJ (1991) Retinoic acid negatively regulates p34cdc2 expression during human neuroblastoma differentiation. Cell Growth Differ 2:487–493PubMedGoogle Scholar
  13. Garaventa A et al. (2003) Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9:2032–2039PubMedGoogle Scholar
  14. Giannini G, Dawson MI, Zhang X, Thiele CJ (1997) Activation of three distinct RXR/RAR heterodimers induces growth arrest and differentiation of neuroblastoma cells. J Biol Chem 272:26693–26701CrossRefPubMedGoogle Scholar
  15. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ (2002) Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway. Cancer Res 62:6756–6763PubMedGoogle Scholar
  16. Jaffe N (1976) neuroblastoma: review of the literature and an examination of factors contributing to its enigmatic character. Cancer Treat Rev 3:61–82PubMedGoogle Scholar
  17. Jogi A et al. (2002) Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA 99:7021–7026PubMedGoogle Scholar
  18. Kaplan DR, Miller FD (2000) Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 10:381–391CrossRefPubMedGoogle Scholar
  19. Keshelava N et al. (2001) Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 61:6185–6193PubMedGoogle Scholar
  20. Khan AA, Villablanca JG, Reynolds CP, Avramis VI (1996) Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation. Cancer Chemother Pharmacol 39:34–41CrossRefPubMedGoogle Scholar
  21. Kohler JA, Imeson J, Ellershaw C, Lie SO (2000) A randomized trial of 13-cis retinoic acid in children with advanced neuroblastoma after high-dose therapy. Br J Cancer 83:1124–1127CrossRefPubMedGoogle Scholar
  22. Le Dourain N, Kalcheim C (1999) The neural crest, 2nd edn. Cambridge University Press, New YorkGoogle Scholar
  23. Li C, Einhorn PA, Reynolds CP (1994) Expression of retinoic acid receptors alpha, beta, and gamma in human neuroblastoma cell lines. Prog Clin Biol Res 385:221–227PubMedGoogle Scholar
  24. Linney E (1992) Retinoic acid receptors: transcription factors modulating gene regulation, development, and differentiation. Curr Top Dev Biol 27:309–350PubMedGoogle Scholar
  25. Lopez-Ibor B, Schwartz AD (1985) Neuroblastoma. Pediatr Clin North Am 32:755–778PubMedGoogle Scholar
  26. Lovat PE et al. (2002) GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of neuroblastoma. Cancer Res 62:5158–5167PubMedGoogle Scholar
  27. Lovat PE et al. (2003a) Bak: a downstream mediator of fenretinide-induced apoptosis of SH-SY5Y neuroblastoma cells. Cancer Res 63:7310–7313PubMedGoogle Scholar
  28. Lovat PE et al. (2003b) Mechanisms of free-radical induction in relation to fenretinide-induced apoptosis of neuroblastoma. J Cell Biochem 89:698–708CrossRefPubMedGoogle Scholar
  29. Lucarelli E, Kaplan DR, Thiele CJ (1995) Selective regulation of TrkA and TrkB receptors by retinoic acid and interferongamma in human neuroblastoma cell lines. J Biol Chem 270:24725–24731CrossRefPubMedGoogle Scholar
  30. Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR, Thiele CJ (1995) Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res 55:1798–1806PubMedGoogle Scholar
  31. Matsuo T, Thiele CJ (1998) p27Kip1: a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line. Oncogene 16:3337–3343CrossRefPubMedGoogle Scholar
  32. Matsushima H, Bogenmann E (1993) Expression of trkA cDNA in neuroblastomas mediates differentiation in vitro and in vivo. Mol Cell Biol 13:7447–7456PubMedGoogle Scholar
  33. Matthay K et al. (1999) Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 341:1165–1173CrossRefPubMedGoogle Scholar
  34. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP (1999) N-(4-hydroxyphenyl)retinamide increases ceramide and reactive oxygen species and induces mixed apoptosis/ necrosis in neuroblastoma cell lines. J Natl Cancer Inst 91:1138–1146CrossRefPubMedGoogle Scholar
  35. Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP (2000) Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 92:1897CrossRefPubMedGoogle Scholar
  36. McLaughlin JE, Urich H (1977) Maturing neuroblastoma and ganglioneuroblastoma: a study of four cases with long survival. J Pathol 121:19–26CrossRefPubMedGoogle Scholar
  37. Nakagawara A, Arima Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM (1993) Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328:847–854CrossRefPubMedGoogle Scholar
  38. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM (1994) Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 14:759–767PubMedGoogle Scholar
  39. Nakamura M, Matsuo T, Stauffer J, Neckers L, Thiele CJ (2003) Retinoic acid decreases targeting of p27 for degradation via an N-myc-dependent decrease in p27 phosphorylation and an N-myc-independent decrease in Skp2. Cell Death Differ 10:230–239CrossRefPubMedGoogle Scholar
  40. Nakamura Y, Ozaki T, Koseki H, Nakagawara A, Sakiyama S (2003) Accumulation of p27 KIP1 is associated with BMP2-induced growth arrest and neuronal differentiation of human neuroblastoma-derived cell lines. Biochem Biophys Res Commun 307:206–213CrossRefPubMedGoogle Scholar
  41. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M (1996) Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334:231–238CrossRefPubMedGoogle Scholar
  42. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, Jacobsen C, Kliemannel M, Schwarz E, Willnow TE, Hempstead BL, Petersen CM (2004) Sortilin is essential for proNGF-induced neuronal cell death. Nature 427:843–848CrossRefPubMedGoogle Scholar
  43. Peverali FA et al. (1996) Retinoic acid-induced growth arrest and differentiation of neuroblastoma cells are counteracted by N-myc and enhanced by max overexpressions. Oncogene 12:457–462PubMedGoogle Scholar
  44. Ponzoni M et al. (1995) Differential effects of N-(4-hydroxyphenyl) retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res 55:853–861PubMedGoogle Scholar
  45. Raaf JH, Cangir A, Luna M (1982) Induction of neuroblastoma maturation by a new chemotherapy protocol. Med Pediatr Oncol 10:275–282PubMedGoogle Scholar
  46. Raffaghello L et al. (2003) Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma. Cancer Lett 197:151–155CrossRefPubMedGoogle Scholar
  47. Reynolds CP (2004) Detection and treatment of minimal residual disease in high-risk neuroblastoma. Pediatr Transplant 8:56–66CrossRefPubMedGoogle Scholar
  48. Reynolds CP, Lemons RS (2001) Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am 15:867–910CrossRefPubMedGoogle Scholar
  49. Reynolds CP et al. (1991) Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res 366:203–211PubMedGoogle Scholar
  50. Reynolds CP, Schindler PF, Jones DM, Gentile JL, Proffitt RT, Einhorn PA (1994) Comparison of 13-cis-retinoic acid to trans-retinoic acid using human neuroblastoma cell lines. Prog Clin Biol Res 385:237–244PubMedGoogle Scholar
  51. Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ (2000) Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med Pediatr Oncol 35:597–602CrossRefPubMedGoogle Scholar
  52. Reynolds CP, Maurer BJ, Kolsenick R (2004) Ceramide synthesis and metabolism as a target of cancer chemotherapy. Cancer Lett 206:169–180CrossRefPubMedGoogle Scholar
  53. Ribatti D et al. (2001) Inhibition of neuroblastoma-induced angiogenesis by fenretinide. Int J Cancer 94:314–321CrossRefPubMedGoogle Scholar
  54. Sawai S, Shimono A, Wakamatsu Y, Palmes C, Hanaoka K, Kondoh H (1993) Defects of embryonic organogenesis resulting from targeted disruption of the N-myc gene in the mouse. Development 117:1445–1455PubMedGoogle Scholar
  55. Scala S et al. (1996) Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Cancer Res 56:3737–3742PubMedGoogle Scholar
  56. Schober A, Wolf N, Kahane N, Kalcheim C, Krieglstein K, Unsicker K (1999) Expression of neurotrophin receptors trkB and trkC and their ligands in rat adrenal gland and the intermediolateral column of the spinal cord. Cell Tissue Res 296:271–279CrossRefPubMedGoogle Scholar
  57. Seeger RC et al. (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111–1116PubMedGoogle Scholar
  58. Shimada H et al. (1984) Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405–416PubMedGoogle Scholar
  59. Sidell N (1982) Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst 68:589–596PubMedGoogle Scholar
  60. Smith J, Fauquet M (1984) Glucocorticoids stimulate adrenergic differentiation in cultures of migrating and premigratory neural crest. J Neurosci 4:2160–2172PubMedGoogle Scholar
  61. Smith MA et al. (1992a) Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer (see comments). J Clin Oncol 10:1666–1673PubMedGoogle Scholar
  62. Smith MA, Parkinson DR, Cheson BD, Friedman MA (1992b) Retinoids in cancer therapy. J Clin Oncol 10:839–864PubMedGoogle Scholar
  63. Stanton BR, Perkins AS, Tessarollo L, Sassoon DA, Parada LF (1992) Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev 6:2235–2247PubMedGoogle Scholar
  64. Sumantran VN, Brederlau A, Funa K (2003) BMP-6 and retinoic acid synergistically differentiate the IMR-32 human neuroblastoma cells. Anticancer Res 23:1297–1303PubMedGoogle Scholar
  65. Teng KK, Hempstead BL (2004) Neurotrophins and their receptors: signaling trios in complex biological systems. Cell Mol Life Sci 61:35–48CrossRefPubMedGoogle Scholar
  66. Thiele CJ, Israel MA (1988) Regulation of N-myc expression is a critical event controlling the ability of human neuroblasts to differentiate. Exp Cell Biol 56:321–333PubMedGoogle Scholar
  67. Thiele CJ, Reynolds CP, Israel MA (1985) Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313:404–406CrossRefPubMedGoogle Scholar
  68. Thiele CJ, Deutsch LA, Israel MA (1988) The expression of multiple proto-oncogenes is differentially regulated during retinoic acid induced maturation of human neuroblastoma cell lines. Oncogene 3:281–288PubMedGoogle Scholar
  69. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J (2001) Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 61:8–13Google Scholar
  70. Villablanca JG et al. (1995) Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 13:894–901PubMedGoogle Scholar
  71. Villablanca JG, Ames MM, Reid JM, Bagniewski PG, Krailo M, Reynolds CP (2002) Phase I trial of oral N-(4-hydroxyphenyl) retinamide (4-HPR) in children with resistant/recurrent solid tumors: a Childrens Cancer Group Study (CCG 09709). Proc Am Soc Clin Oncol 21:1558Google Scholar
  72. Wakamatsu Y, Watanabe Y, Nakamura H, Kondoh H (1997) Regulation of the neural crest cell fate by N-myc: promotion of ventral migration and neuronal differentiation. Development 124:1953–1962PubMedGoogle Scholar
  73. Warrell RP Jr et al. (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324:1385–1393PubMedGoogle Scholar
  74. Wartiovaara K, Barnabe-Heider F, Miller FD, Kaplan DR (2002) N-myc promotes survival and induces S-phase entry of postmitotic sympathetic neurons. J Neurosci 22:815–824PubMedGoogle Scholar
  75. Woo CW, Lucarelli E, Thiele CJ (2004) NGF activation of TrkA decreases N-myc expression via MAPK path leading to a decrease in neuroblastoma cell number. Oncogene 23:1522–1530CrossRefPubMedGoogle Scholar
  76. Wu J, Saint-Jeannet JP, Klein PS (2003) Wnt-frizzled signaling in neural crest formation. Trends Neurosci 26:40–45CrossRefPubMedGoogle Scholar
  77. Yamashiro DJ et al. (1997) Expression and function of Trk-C in favourable human neuroblastomas. Eur J Cancer 33:2054–2057CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Carol J. Thiele
  • C. Patrick Reynolds

There are no affiliations available

Personalised recommendations